OncoOne develops precision therapies targeting tumor-associated molecules and oxMIF to address chronic inflammation and cancer, significantly improving patient outcomes. Their proprietary platforms, including PreTarg-it® for radioimmunotherapy, aim to enhance treatment efficacy in oncology and provide targeted antibody-based therapies for inflammation.
Funding
$14.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer and chronic inflammation treatments often lack precision, leading to limited efficacy and potential harm to healthy tissues. Existing therapies may not effectively target tumor-associated molecules or inflammation sites, resulting in suboptimal patient outcomes and reduced quality of life.
Solution
OncoOne is developing precision medicines, including antibody-based therapies and radioimmunotherapies, designed to target tumor-associated molecules and address chronic inflammation. The company's approach leverages the discovery of oxMIF, a molecule exclusively found at inflammation sites, and its proprietary PreTarg-it® platform for targeted radioimmunotherapy. By delivering therapies directly to affected organs and tumor sites, OncoOne aims to improve treatment efficacy, minimize off-target effects, and enhance patient outcomes in oncology and chronic inflammatory diseases.
Target Audience
The primary target audience includes patients with cancer and chronic inflammatory diseases, as well as healthcare providers and researchers seeking more effective and targeted treatment options.
Features
- Anti-oxMIF Platform: A novel antibody pipeline targeting oxMIF to unlock new therapeutic approaches for chronic inflammation.
- PreTarg-it® Platform: A modular platform using bispecific antibodies for pre-targeted radioimmunotherapy in oncology.
- Antibody Design: Cutting-edge antibody technology to design novel therapeutics with enhanced targeting capabilities.
- Targeted Therapies: Precision medicines designed to selectively target tumor-associated molecules and inflammation sites.